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Conclusion: The most common genotype was 1a that it
was accordant to studies that conducted in general popula-
tion in Iran.
doi:10.1016/j.ijid.2008.05.1255
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Background: Chronic infection of hepatitis C virus (HCV)
may lead to hepatic ﬁbrosis and the precise mechanisms
remain unclear. Our previous study indicated that E2 protein
may involve in the hepatic ﬁbrogenesis via an up-regulation
of ﬁbrosis-related proteins.
Methods: To further conﬁrm this ﬁnding, E2 gene silenc-
ing and a treatment with silibinin was conducted on
E2-expressing cells and RT-PCR analysis was performed.
Results: E2-enhanced expression of ﬁbrosis-related
molecules, including alpha-SMA, collagen alpha(I), TGF-1,
connective tissue growth factor (CTGF), IL-6 and IL-1, MMP-
2, were all abolished by a treatment with siRNA speciﬁc
for E2. Furthermore, a treatment with silibinin, a potent
antioxidant, was conducted to gain similar results.
Conclusion: These results further prove that E2 protein
may involve in the process of hepatic ﬁbrogenesis and E2-
related ﬁbrosis may be, at least in part, through an oxidative
damage-related pathway.
doi:10.1016/j.ijid.2008.05.1256
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Introduction: Impaired natural killer (NK) cell activity
contributes to viral persistence in HCV infection. Recent
studies demonstrated that in tumors regulatory T cells (Treg)
- via secreting TGF-beta1 - down-regulate NKG2D killer
activator receptor and are responsible for poor NK cytox-
icity. Since in chronic hepatitis C plasma TGF-beta1 level is
increased, we analyzed the expression of NKG2D on NK and
T cells and its correlation with the percentage of Treg cells
and TGF-beta1 levels.
Methods: The peripheral CD4+CD25high+ Treg cells,
NKG2D+ NK and T cells were determined by FACS, plasma
TGF-beta1 levels by ELISA. Forty three patients with active
chronic hepatitis C, 10 sustained virological responders
(SVR) and 15 healthy controls were enrolled.
Results: In patients with chronic hepatitis C the NKG2D
expression was down-regulated both on NK (7,9 vs. 20,9%)
and T cells (18 vs. 26,3%) compared to controls. Impaired
expression of NKG2D was associated with increased pro-
portion of CD4+CD25high+ Treg cells (4,6 vs. 3,1%) and
increased TGF-beta1 levels (15 vs.9 pg/ml) compared to con-
trols. TGF-beta1 inversely correlated with NKG2D expression
on NK cells. In SVR group, the percentage of Treg cells
(1,7± 0,2%), TGF-beta1 levels (11,6 pg/ml) and NKG2D
expression (NK:17%, T:20,9%) were comparable to controls.
Discussion/Conclusion: Our data suggest that TGF-beta1
- secreted by regulatory T cells - may be responsible for
impaired NK cell function via down-regulating NKG2D. Thus,
TGF-beta1 antagonism or soluble NKG2D ligands may provide
the basis of a novel immunotherapy to improve the function
of NK and T cells in chronic hepatitis C.
doi:10.1016/j.ijid.2008.05.1257
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Objective: A nation-wide retrospective analysis has been
performed in order to assess the efﬁcacy of antiviral therapy
for patients with chronic hepatitis B and C representing the
entire population that needed treatment in Hungary, during
a seven-year period. In addition, results of a prospective
study including patients with chronic hepatitis C are also
presented.
Patients and Methods: Of 220 patients with hepatitis
B, 112 were treated with standard interferon-alpha (IFN),
23 with pegylated interferon-alpha-2a (PEG-IFN) and 85
with lamivudine (LAM), and the ratio of HBeAg seroconver-
sion and/or undetectable HBV-DNA has been assessed. Of
2442 patients with hepatitis C, 333 were treated with IFN
monotherapy, 1122 with IFN + ribavirin (RBV) and 987 with
PEG-IFN + RBV for 6—12 months. In the prospective study, 69
patients with chronic hepatitis C were enrolled and treated
with PEG-IFN alfa-2a + RBV. The rate of sustained virological
response (SV), the predictors of outcome and the adverse
effects of treatment were evaluated.
Results: For HBV patients IFN, PEG-IFN and LAM provided
31, 30, and 33% SVR rate, respectively. In chronic hepatitis C,
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a continuous improvement was noted in sustained virological
response, from 13% with IFN monotherapy to 31% with PEG-
IFN +RBV, while even a 48% sustained virological response
has been achieved in the prospective trial. The predictors
of outcome were the 4-week ‘rapid’ and 12-week ‘early’
virological responses, female gender, age, BMI and adher-
ence. The most frequent complications of the treatment
were cytopenia, haemolysis and depression, occurring in 9%
of patients.
Conclusion: Unlike in HBV infection, in HCV hepatitis the
efﬁcacy of antiviral treatment has gradually improved in our
everyday clinical practice. To manage the growing popula-
tions of hard-to-treat patients with chronic viral hepatitis,
there is a need for more effective treatment modalities,
including optimised, individualised dosing and novel antivi-
ral agents.
doi:10.1016/j.ijid.2008.05.1258
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Aims: Since in the outcome of chronic hepatitis C virus
(HCV) infection the progression of hepatic ﬁbrosis is essen-
tial, and interferon (IFN) treatment is supposed to inhibit
ﬁbrogenesis, we wanted to compare changes in three non-
invasive ﬁbrosis markers in chronic HCV hepatitis.
Methods: Plasma levels of TGF-beta1 and hyaluronic acid
(HA) were determined by ELISA, procollagen-III-peptide (P-
III-P) levels by RIA in 49 patients with chronic hepatitis C
before the antiviral treatment and 1, 3, 6 and 12 months
thereafter. Twenty two patients became responders (R), 27
patients were non-responders (NR). Thirty healthy controls
were also studied. Correlation between TGF-beta1, HA, P-
III-P levels and the histological activity and the ﬁbrosis score
in liver biopsy was evaluated.
Results: Pretreatment plasma TGF-beta1, HA and P-
III-P levels were signiﬁcantly (p < 0,01) increased in both
responder and non-responder patients compared to con-
trols. HA levels correlated with ﬁbrosis score, TGF-beta1
with histological activity index. PEG-IFN + ribavirin treat-
ment decreased both TGF-beta1 and HA levels, not only
in responders but also in non-responders. The reduction of
ﬁbrosis marker levels was more considerable after 6 months
of antiviral therapy, and remained sustained even 6 months
after the treatment. No correlation was found betwen ﬁbro-
sis markers and HCV RNA levels.
Conclusion: PEG-IFN plus Ribavirin treatment decreased
TGF-beta1 and hyaluronic acid levels independently of
virological response. These data suggest that antiviral
treatment may have antiﬁbrotic effect even in virological
non-responders.
doi:10.1016/j.ijid.2008.05.1259
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Infections with HBV and HCV are the most common cause
of chronic hepatitis and their consequence may be liver cir-
rhosis and/or hepatocellular carcinoma. Co-infection with
these viruses is relatively common and it remains serious
epidemiological and clinical problem.
Objective: Evaluation of impact of co-infection with HBV
and HCV on clinical picture of chronic hepatitis.
Material and Methods: retrospective analysis of 238
patients among 1330 patients hospitalized in years
2001—2005 in Department of Infectious Diseases in Wro-
claw due to diagnostics of chronic hepatitis C. Patients
were divided into groups according to their serological sta-
tus: group A - anti-HCV positive, anti-HBc negative patients
(n = 123), group B - anti-HCV positive, anti-HBc positive,
HBsAg negative patients (n = 115). Groups A and B were
randomly selected according to age, sex, duration of HCV
infection. Some biochemical features, histological pattern
(modiﬁed HAI scale) and virological status were evaluated.
Dates were statistical analyzed by chi-square Wald test.
Results: Median value of viral load in group A was
1,4× 106 and in group B was 1,0× 106 (p > 0,05). There were
no statistical correlation of GOT, GPT, GGTP and PLT values
in these two groups. Grading in group A was 1,64 and in
group B was 1,62 (p > 0,5). Relevant differences in ﬁbrosis
stage was observed between the groups - staging in group A
was 1,87 and in group B 1,37 (p < 0,05)).
Conclusions: Past HBV infection and possible minireplica-
tion has no impact on HCV viremia. Fibrosis of the liver was
surprisingly higher in HCV monoinfection patients. Further
investigation in large and homogenous groups of patients are
needed.
doi:10.1016/j.ijid.2008.05.1247
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Background: Current therapy for HCV consists of a com-
bination of synthetically-modiﬁed interferon, pegylated
interferon, and ribavirin, to which nearly 50% of patients
do not respond. Clinical trials have demonstrated that this
